Myelodysplastic Syndrome (MDS): Practice Essentials, Pathophysiology, Etiology



schizophrenia chromosome :: Article Creator

Pig Kidney Transplants, New Schizophrenia Drug: Here Are 5 Of The Biggest Medical Breakthroughs In 2024

From a pig kidney transplant to restoring genetic deafness, 2024 was a year full of medical breakthroughs.

The breakthroughs include the discovery of a cause of an autoimmune disease, the development of a "game-changing" drug and potential hope for those experiencing end-stage organ failure.

Here are five of the biggest highlights in medical achievements this year:

MORE: FDA approves gene therapies for sickle cell disease, a 'functional cure' for many Gene therapy restores hearing in children

Children with hereditary deafness regained their hearing thanks to a type of gene therapy, according to the results of a clinical trial published in the medical journal The Lancet in January.

Investigators from Mass Eye and Ear, a specialty hospital in Boston, examined six children who had a form of genetic deafness called DFNB9, which is caused by a gene mutation that interferes with the transmission of sound signals from the ear to the brain.

A still image taken from video of a study on gene therapy restoring hearing in children with hereditary deafness.

Mass General Brigham

Gene therapy involved the use of an inactive virus carrying a functioning version of the gene, which was introduced into the inner ears of the six children.

After 26 weeks, five of the six children recovered their hearing and could even conduct "normal conversation."

"Children with this genetic hearing loss…the only treatment option for them until now is [a] cochlear implant," Dr. Zheng-Yi Chen, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear and study co-investigator, told ABC News. "And of course, [a] cochlear implant can help them tremendously, but it's with its own limitations."

"But with this gene therapy, the children regain hearing, and they were able to speak. So, in a way, the life is totally transformed," he continued. "This study really opened up the whole field that, in the future, we'll be able to develop a treatment for other [types] of genetic hearing loss, for which there is no treatment at all at the moment."

Groundbreaking animal organ transplant

Surgeons at Massachusetts General Hospital (MGH) conducted the world's first genetically-edited pig kidney transplant into a living human in March 2024.

During a four-hour procedure, a surgical team connected the pig kidney's blood vessels and ureter - the duct that carries urine from the kidney to the bladder - with those of 62-year-old Richard Slayman, a man living with end-stage kidney disease.

Surgeons perform the world's first genetically modified pig kidney transplant into a living human at Massachusetts General Hospital, March 16, 2024.

Massachusetts General Hospital

"For patients with kidney failure, we know that transplantation is the best treatment option, but unfortunately, we face an immense organ shortage," Dr. Leonardo Riella, medical director of kidney transplantation at MGH, told ABC News. "So, we have over 100,000 patients waiting for a kidney transplant in the U.S., and more than 17 patients die every day on the waiting list."

"So, the idea here is, how can we overcome this organ shortage barrier? And having kidneys from another species that could be delivered in a timely manner for these patients once they develop kidney failure could be game-changing for the entire field," he added.

Slayman passed away in May of this year, but there is no evidence it was the result of the transplant, according to MGH.

Riella said over the course of Slayman's care, much was learned about how to best deliver care when using animal organs for transplants in the hopes of making the treatment more widely available to patients waiting for a new organ.

A cause of lupus discovered

A team at Brigham & Women's Hospital and Northwestern Medicine said they have discovered a cause of the autoimmune disease lupus and a possible way to reverse it.

Lupus sees the body's immune system mistakenly attack its own healthy cells and tissues, which can cause inflammation and damage in organs or systems, according to the Centers for Disease Control and Prevention.

MORE: Woman speaks out after receiving gene-edited pig kidney transplant

In a study, published in the journal Nature in July, researchers compared blood samples from 19 lupus patients to 19 patients without the condition and found imbalances in the types of T-cells lupus patients produce.

T-cells are a certain type of white blood cell that plays a crucial role in the body's immune response to the disease.

"We've identified a fundamental imbalance in the immune responses that patients with lupus make, and we've defined specific mediators that can correct this imbalance to dampen the pathologic autoimmune response," co-corresponding author Dr. Deepak Rao, a rheumatologist at Brigham and Women's Hospital and co-director of its Center for Cellular Profiling, said in a press release at the time.

1st new class of schizophrenia drug in more than 3 decades

In September, the FDA approved the first new class of drug to treat people with schizophrenia in more than 30 years.

The pill, called Cobenfy - manufactured by Bristol Myers Squibb - combines two drugs, xanomeline and trospium chloride, and is taken twice a day.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.

Bristol Myers Squibb

Clinical trials showed the combination helped manage schizophrenia symptoms such as hallucinations, delusions and disorganized thinking.

Dr. René Kahn, chair of psychiatry at the Icahn School of Medicine at Mount Sinai, said it took many years to develop the first medications for schizophrenia, which are effective in preventing psychosis and work by blocking dopamine receptors.

"Blocking the dopamine receptor directly or indirectly is very unpleasant. Sometimes for patients, they can have unpleasant side effects. It can decrease their energy, it can make them feel depressed, and it can give them Parkinsonian side effects," Kahn told ABC News.

He described Cobenfy as "game-changing in the sense that this is the first drug that doesn't directly - with the emphasis on directly - influence the dopamine system and certainly doesn't block dopamine receptors. So that's very important, because it may show that we don't have to directly block or affect the dopamine system but can do that through a different mechanism."

Kahn said the next step will be monitoring the drug as it is prescribed to thousands of schizophrenia patients to ensure it works and that side effects are minimal.

1st over-the-counter combo flu and COVID test outside of emergency use

The FDA authorized the first over-the-counter combination COVID-19 and flu test outside of emergency use in October. 

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test seen here.

Healgen

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test can be purchased at a pharmacy or other stores without a prescription.

While there are other over-the-counter combination tests currently available, this is the first to be marketed to consumers using the traditional approval pathway outside of a public health emergency, according to the FDA.


Schizophrenia's Unique Brain Network Identified

Summary: A new study has identified a distinct brain network connecting areas of atrophy associated with schizophrenia, offering a unified view of its neuroanatomy. By analyzing data from over 90 studies and more than 8,000 participants, researchers created an atrophy connectivity map that overlaps with regions linked to schizophrenia, such as the insula and hippocampus.

This network remained consistent across stages and symptoms of the disease and was distinct from other psychiatric or neurological conditions. These findings could guide future personalized treatments and a clinical trial targeting this network with transcranial magnetic stimulation.

Key Facts

  • Unified Network: Schizophrenia is associated with a distinct brain network linking areas of atrophy across stages and symptoms.
  • Specific Regions: Key regions include the bilateral insula, hippocampus, and fusiform cortex.
  • Therapeutic Potential: Findings support targeted brain stimulation trials to refine treatment strategies.
  • Source: Brigham and Women's Hospital

    A new study led by investigators from Mass General Brigham has identified a unique brain network that links varied patterns of brain atrophy, or shrinkage, associated with schizophrenia.

    By combining neuroimaging data from multiple studies involving more than 8,000 participants, the research team found a specific connectivity pattern of atrophy that was present across different stages and symptoms of schizophrenia — and distinct from brain networks associated with other psychiatric disorders.

    The findings will help to guide a clinical trial that will start recruiting patients soon and will assess brain stimulation sites connected to the schizophrenia network.

    Despite large-scale efforts to resolve the neuroanatomy of schizophrenia, varied results and methodological differences have limited experts' understanding of circuits linked to brain atrophy. Credit: Neuroscience News

    Results are published in Nature Mental Health. 

    "We looked for common threads among reports on how schizophrenia affects the brain," said corresponding author Ahmed T. Makhlouf, MD, of the Center for Brain Circuit Therapeutics and medical director of the Brigham and Women's Hospital Psychosis Program.

    "We found that there's atrophy in places all over the brain, but they're all connected to a single network." 

    Despite large-scale efforts to resolve the neuroanatomy of schizophrenia, varied results and methodological differences have limited experts' understanding of circuits linked to brain atrophy. 

    "One explanation could be that everyone's actually looking at the same thing from a different vantage point. If multiple people try to feel different parts of an elephant with their eyes closed, they're going to describe different things," said senior author Shan H. Siddiqi, MD, a psychiatrist at the Brigham's Center for Brain Circuit Therapeutics.

    "Our approach with this study was to try to reconstruct the elephant." 

    The research examined data from 90 studies involving atrophy in schizophrenia. The dataset included ​​1,636 patients with recently diagnosed schizophrenia, 2,120 individuals with chronic disease and just over 6,000 healthy people.

    The study also examined results from 927 individuals and 580 individuals with genetic or clinical (based on early symptoms) high risk of developing schizophrenia, respectively. 

    First, the investigators constructed a common brain map combining the widespread locations of atrophy in schizophrenia. Then, they used a technique known as coordinate network mapping (CNM) to estimate the overlap between atrophy locations and functional brain networks.

    The resulting atrophy connectivity map overlapped with schizophrenia-associated brain regions, including the bilateral insula, hippocampus and fusiform cortex.

    Finally, the researchers showed that these maps differed from brain connectivity maps developed for aging patients or those with conditions like Alzheimer's disease, major depressive disorder or substance use disorders — indicating the network was specific to schizophrenia.  

    The researchers found that the network was similar across patients with contrasting symptoms or at different stages of schizophrenia and did not significantly change with antipsychotic treatments.

    Patients at high risk of developing schizophrenia shared similarities in atrophy, but there was a unique connectivity pattern in patients who had progressed to clinical disease. The authors suggest that further understanding of atrophy patterns in high-risk individuals could help predict likelihood of developing schizophrenia.

    The researchers note that future studies with patient-specific connectomes could provide individualized insights. They also note that a clinical trial is planned that will use transcranial magnetic stimulation to assess connectivity of stimulation sites to the identified schizophrenia network. 

    "There is a debate in the field as to whether or not schizophrenia is a neurodegenerative disorder," said Makhlouf. "Our study indicates that there is a unique and unified network that might be a core characteristic of schizophrenia." 

    Authorship: In addition to Makhlouf and Siddiqi, Mass General Brigham authors include William Drew, Jacob L. Stubbs, Joseph J. Taylor, David Silbersweig, Michael D. Fox. Additional authors include Donato Liloia and Jordan Grafman. 

    Disclosures: Siddiqi holds intellectual property related to using individualized resting-state network mapping for targeting TMS, filed in 2016, which has not generated royalties and is unrelated to this work.

    Siddiqi also serves as a scientific consultant for Magnus Medical, has received investigatorinitiated research funding from Neuronetics (2019) and Brainsway (2022), received speaking fees from Brainsway (2021) and Otsuka (for PsychU.Org, 2021), and holds shares in Brainsway (publicly traded) and Magnus Medical (privately held).

    Fox is a scientific consultant for Magnus Medical and owns separate intellectual property related to using functional connectivity to target TMS for depression, filed in 2013, which has not generated royalties and is unrelated to this work  Funding: Harvard Medical School (Dupont Warren Fellowship Award, Livingston Award), the NIH (grant no. R01MH113929, K23MH129829, R01MH113929, R21MH126271, R56AG069086, R01MH115949, R01AG060987, K23MH121657, R21MH126271, R01MH136248), Canadian Institutes of Health Research Vanier Scholarship and a University of British Columbia Friedman Award for Scholars in Health, Brain and Behavior Research Foundation Young Investigator Grant (no. 31081), Sidney R. Baer, Jr. Foundation, Baszucki Brain Research Fund, the Nancy Lurie Marks Foundation, the Kaye Family Research Endowment, the Baszucki Brain Research Fund, the Brain and Behavior Research Foundation Young Investigator Grant, and the Baszucki Brain Research Fund and the Department of Veterans Affairs (grant no.I01CX002293). 

    Author: Cassandra FaloneSource: Brigham and Women's HospitalContact: Cassandra Falone – Brigham and Women's HospitalImage: The image is credited to Neuroscience News

    Original Research: Closed access."Heterogenous Patterns of Brain Atrophy in Schizophrenia Localize to A Common Brain Network" by Ahmed T. Makhlouf et al. Nature Mental Health

    Abstract

    Heterogenous Patterns of Brain Atrophy in Schizophrenia Localize to A Common Brain Network

    Understanding the neuroanatomy of schizophrenia remains elusive due to heterogeneous findings across neuroimaging studies.

    Here we investigated whether patterns of brain atrophy associated with schizophrenia would localize to a common brain network using a coordinate network mapping meta-analysis approach.

    Utilizing the human connectome as a wiring diagram, we identified a connectivity pattern, a schizophrenia network, uniting heterogeneous results from 90 published studies of atrophy in schizophrenia (total n > 8,000).

    This network was specific to schizophrenia, differentiating it from atrophy in individuals at high risk for psychosis (n = 3,038), normal aging (n = 4,195), neurodegenerative disorders (n = 3,707) and other psychiatric conditions (n = 3,432).

    The network was also stable with disease progression and across different clusters of schizophrenia symptoms.

    Patterns of brain atrophy in schizophrenia were negatively correlated with lesions linked to psychosis-related thought processes in an independent cohort (n = 181).

    Our results propose a unique, stable, and unified schizophrenia network, addressing a significant portion of the heterogeneity observed in previous atrophy studies.


    I Have Schizophrenia — This Is What It's Like To Live With My Freaky Hallucinations

    A woman on TikTok is bravely sharing her experience living with schizophrenia.

    Last week, she detailed her hallucinatory symptoms in a post that went viral with more than 5.1 million views on the social media app.

    More than 200,000 people in the US are diagnosed with schizophrenia annually — and one of those recently diagnosed patients is speaking out on TikTok. Katarzyna Bialasiewicz/Photographee.Eu

    She employs her video editing skills to demonstrate the phenomenon — which she describes as seeing "black masses" rather than people.

    "Most of what I will see is that [there is] a black shadow behind me — like this," she says into the camera just before the footage cuts to a loosely formed silhouette standing before a doorway.

    "Or I will see them peek around the corner — like this," she continued, cutting away to show the same doorframe and her own face slowly peering beyond the threshold of the same doorway.

    "This is a major reason why I don't have doors [open]," she added. "They will look through the crack of the door and just stare at me. It's f—king freaky."

    "Or I'll be in my living room and they'll be looking at me from the kitchen."

    While usually haunted by shadowy figures, she claimed to have also seen "zombie-like" visions in the past. "But I was really close to a mental breakdown," she explained.

    TikTok user @thotty.Thoughts.Only is sharing her experience living with schizophrenia, including some subtle signs of disease onset. "Collages I made while unmediated for schizophrenia," the caption reads. @thotty.Thoughts.Only/TikTok

    TikTok users reacted to her video with sympathy.

    "You're a strong woman," read one of the top comments.

    "I'm so sorry you experienced this. I'm horrified." added another.

    Schizophrenia is a chronic mental disorder that affects how people perceive reality, leading to hallucinations, delusions, disorganized thinking and speech, paranoia and time gaps.

    More than 200,000 people in the US are living with schizophrenia, for which there is no cure. The cause of schizophrenia is still unknown, but research suggests a combination of genetic and environmental factors are likely to encourage its onset.

    In another recent post, the "recently diagnosed" patient described the long-term effects of schizophrenia — specifically, gray matter volume reduction in the brain.

    Gray matter is a type of brain tissue that processes most information the brain receives, including physical sensation, visual perception, movement, speech and memory.

    "The longer that you go without treating your schizophrenia … the less gray matter you have in your brain," she said, adding that she'll likely be on medication to reduce her symptoms for the rest of her life.

    She went on to warn viewers of tell-tale symptoms, urging those who have the same experience to contact a doctor without delay.

    "If you are having a lot of background noise in your brain … go see somebody," she began. "If you're seeing things peak around the corner, you see things hover, black masses … go see somebody."

    "If you are experience thoughts that are not your original thoughts … please go get help."

    "Your life depends on it."






    Comments